Investigator, The Feinstein Institute for Medical Research
Chief, Division of Rheumatology and Allergy-Clinical Immunology, North Shore-LIJ Health System
Professor of Medicine, Hofstra North Shore-LIJ School of Medicine
Phone: (516) 708-2550
Dr. Richard Furie, chief of the Division of Rheumatology and Allergy-Clinical Immunology at North Shore-LIJ Health System, is a rheumatologist who for the last several decades has focused on patient care, physician education and clinical research in the area of anti-rheumatic drug development.
He directs The Program in Novel Therapeutics, the health system’s clinical research program in musculoskeletal disease. He also directs North Shore-LIJ’s Systemic Lupus Erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE.
Regarded as one the senior rheumatologists in the New York metropolitan area, Dr. Furie has been on the boards of directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America. He is also a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America, as well as its Lupus News editorial board. In addition, Dr. Furie is on the Medical and Scientific Advisory Board of the SLE Foundation and the Alliance for Lupus Research Scientific Advisory Board.
Dr. Furie has served on many committees of the American College of Rheumatology, and has recently been appointed to the college’s board of directors.
The goal of Dr. Furie’s proposed research is to investigate the signaling pathways in myeloproliferative diseases over the course of the disease. Understanding these mechanisms may allow for the development of more efficacious and better targeted therapies.
This approach requires samples from individual patients with myeloproliferative diseases. With over 25 years’ experience focusing on the treatment of hematologic malignancies, Dr. Furie has the expertise, leadership and motivation necessary to successfully carry out the proposed work. He has served as principal investigator or co-investigator for many clinical trials involving the treatment of patients with myelodysplastic syndrome and leukemia, including studies involving close collaboration between the clinician and basic science laboratory.
This has been done with great success in chronic lymphocytic leukemia where serial samples over time have been obtained and studied in collaboration with basic science laboratories. Dr. Furie has been an active member of the National Cancer Institute-sponsored Community Clinical Oncology Program, participating in multiple cooperative group clinical trials for patients with hematologic malignancies. He also successfully administered the projects (e.g., staffing, research protections, budget), collaborated with other researchers and produced more than 100 peer-reviewed publications based upon these projects.
As a result of his previous experience, Dr. Furie is aware of the requirements to successfully undertake a clinical trial following good clinical practice guidelines. He has demonstrated a record of successful and productive myeloproliferative disease research in this patient population.
Cornell University Medical College
The New York Hospital
Field of Study: Internal Medicine
The New York Hospital
Field of Study: Assistant Resident
1984-1987 Instructor, Cornell University Medical College (CUMC)
1987-1993 Assistant Professor of Medicine, CUMC
1993-1996 Associate Professor of Clinical Medicine, CUMC
1996-1997 Adjunct Associate Professor of Clinical Medicine, CUMC
1996-2010 Associate Professor of Medicine, NYU School of Medicine
2007-2011 Professor of Clinical Medicine, Albert Einstein College of Medicine
2009-present Professor of Medicine, Hofstra North Shore-LIJ School of Medicine
2009-present Department of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
1984-1985 Assistant Attending, The New York Hospital
1985-2010 Assistant Attending, The Hospital for Special Surgery
1985-1988 Assistant Attending, North Shore University Hospital (NSUH)
1988-1993 Senior Assistant Attending, NSUH
1993-1999 Associate Attending, NSUH
1999-present Attending, NSUH
2000-2004 Chief, Division of Rheumatology and Allergy-Clinical Immunology (NSUH)
2002-present Investigator, North Shore-Long Island Jewish Research Institute
2005-present Chief, Div. of Rheumatology and Allergy-Clinical Immunology (NSLIJHS)
1985-1999 Director, Arthritis and SLE Clinics
1986-present Director, Systemic Lupus Erythematosus and Autoimmune Disease
1986-2007 Director, Rheumatology Fellowship Training Program
1990-present Director, The Program in Novel Therapeutics
1995-2000 Director, Clinical Rheumatology, NSUH, Manhasset
2000-2004 Chief, Division of Rheumatology and Allergy-Clinical Immunology, NSUH
2005-present Chief, Division of Rheumatology and Allergy-Clinical Immunology, North Shore-LIJ
1974 A.B. Magna cum laude
1981 Assistant Chief Resident, New York Hospital
1982-1983 Fellow of the Arthritis Foundation
1997 Top Doctors: NY Metro Area
1999 Top Doctors: NY Metro Area
2002, 2010 New York Magazine Best Doctors
2005 America’s Top Physicians
- Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. “Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study.” Arthritis Rheum 2010; 62(1): 201-210.
- Arad A, Proulle V, Furie RA, Furie BC, Furie B. “β2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.” Blood 2011; 117(12): 3453-9.
- Merrill JT, Buyon JP, Furie RA, Latinis KM, Gordon C, Hsieh HJ, Brunetta P. “Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).” Lupus. 2011; 20(7):709-16.
- Furie RA, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham W, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF. “A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with active systemic lupus erythematosus.” Arthritis Rheum 2011; 63(12):3918-3930.
- Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; for the LUNAR Investigator Group. “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study.” Arthritis Rheum 2012; 64(4):1215-26.
- Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA. “Effects of belimumab, a B-lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase 3 trials.” Ann Rheum Dis 2012; [Epub ahead of print]
- Horowitz D, Furie R. “Does belimumab reduce disease activity in adults with systemic lupus erythematosus?” Clin Med Rev Ther 2012; 4:71-78.
- Horowitz D, Marder G, Furie R: “Musculoskeletal System: Articular Disease, Bone Metabolism in Systemic Lupus Erythematosus.” Edited by Lahita RG. New York, Elsevier, 2010.
- Bogachuk E, Furie R: “Systemic lupus erythematosus in Perioperative Management of the Patient with Rheumatic Disease.” Edited by Brian Mandell. Springer, in press.